Found 48 hits of Enzyme Inhibition Constant Data Target/Host
(Institution) | Ligand | Target/Host
Links | Ligand
Links | Trg + Lig
Links | Ki
nM | ΔG°
kJ/mole | IC50
nM | Kd
nM | EC50/IC50
nM | koff
s-1 | kon
M-1s-1 | pH | Temp
°C |
|---|
Receptor-type tyrosine-protein kinase FLT3
(Homo sapiens (Human)) | BDBM112481
(US8623885, 22)Show SMILES OCC(=O)N1CCc2nc(Nc3ncc4c5ccncc5n(C5CCCC5)c4n3)ccc2C1 Show InChI InChI=1S/C24H25N7O2/c32-14-22(33)30-10-8-19-15(13-30)5-6-21(27-19)28-24-26-11-18-17-7-9-25-12-20(17)31(23(18)29-24)16-3-1-2-4-16/h5-7,9,11-12,16,32H,1-4,8,10,13-14H2,(H,26,27,28,29) | PDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
| PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 0.650 | n/a | n/a | n/a | n/a | 7.6 | n/a |
Amgen Inc.
US Patent
| Assay Description
The FLT3 inhibitory activity of the CDK4/6-FLT3 inhibitors was determined with a HTRF kinase assay. The FLT3 enzyme (GST-FLT3 fusion) was purchased f... |
US Patent US8623885 (2014)
BindingDB Entry DOI: 10.7270/Q2DZ06Z1 |
More data for this
Ligand-Target Pair | |
Receptor-type tyrosine-protein kinase FLT3
(Homo sapiens (Human)) | BDBM112460
(US8623885, 1)Show SMILES C[C@H]1CC[C@@H](CC1)n1c2cnccc2c2cnc(Nc3ccc4CNCCc4n3)nc12 |r,wU:4.7,wD:1.0,(4.13,-4.37,;3.73,-2.88,;4.82,-1.79,;4.42,-.3,;2.93,.09,;1.84,-.99,;2.24,-2.48,;2.53,1.58,;3.44,2.83,;4.97,2.99,;5.6,4.4,;4.69,5.64,;3.16,5.48,;2.53,4.07,;1.07,3.6,;-.26,4.37,;-1.6,3.6,;-1.6,2.06,;-2.93,1.29,;-2.93,-.25,;-1.6,-1.02,;-1.6,-2.56,;-2.93,-3.33,;-2.93,-4.87,;-4.26,-5.64,;-5.6,-4.87,;-5.6,-3.33,;-4.26,-2.56,;-4.26,-1.02,;-.26,1.29,;1.07,2.06,)| Show InChI InChI=1S/C24H27N7/c1-15-2-5-17(6-3-15)31-21-14-26-10-8-18(21)19-13-27-24(30-23(19)31)29-22-7-4-16-12-25-11-9-20(16)28-22/h4,7-8,10,13-15,17,25H,2-3,5-6,9,11-12H2,1H3,(H,27,28,29,30)/t15-,17- | PDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 1.30 | n/a | n/a | n/a | n/a | 7.6 | n/a |
Amgen Inc.
US Patent
| Assay Description
The FLT3 inhibitory activity of the CDK4/6-FLT3 inhibitors was determined with a HTRF kinase assay. The FLT3 enzyme (GST-FLT3 fusion) was purchased f... |
US Patent US8623885 (2014)
BindingDB Entry DOI: 10.7270/Q2DZ06Z1 |
More data for this
Ligand-Target Pair | |
Receptor-type tyrosine-protein kinase FLT3
(Homo sapiens (Human)) | BDBM112475
(US8623885, 16)Show SMILES C[C@H]1CC[C@@H](CC1)n1c2cnccc2c2cnc(Nc3ccc4CNCC(O)c4n3)nc12 |r,w:26.28,wU:4.7,wD:1.0,(4.8,-4.37,;4.4,-2.88,;5.49,-1.79,;5.09,-.3,;3.6,.09,;2.51,-.99,;2.91,-2.48,;3.2,1.58,;4.11,2.83,;5.64,2.99,;6.26,4.4,;5.36,5.64,;3.83,5.48,;3.2,4.07,;1.74,3.6,;.4,4.37,;-.93,3.6,;-.93,2.06,;-2.26,1.29,;-2.26,-.25,;-.93,-1.02,;-.93,-2.56,;-2.26,-3.33,;-2.26,-4.87,;-3.6,-5.64,;-4.93,-4.87,;-4.93,-3.33,;-6.26,-2.56,;-3.6,-2.56,;-3.6,-1.02,;.4,1.29,;1.74,2.06,)| Show InChI InChI=1S/C24H27N7O/c1-14-2-5-16(6-3-14)31-19-12-25-9-8-17(19)18-11-27-24(30-23(18)31)29-21-7-4-15-10-26-13-20(32)22(15)28-21/h4,7-9,11-12,14,16,20,26,32H,2-3,5-6,10,13H2,1H3,(H,27,28,29,30)/t14-,16-,20? | PDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 1.40 | n/a | n/a | n/a | n/a | 7.6 | n/a |
Amgen Inc.
US Patent
| Assay Description
The FLT3 inhibitory activity of the CDK4/6-FLT3 inhibitors was determined with a HTRF kinase assay. The FLT3 enzyme (GST-FLT3 fusion) was purchased f... |
US Patent US8623885 (2014)
BindingDB Entry DOI: 10.7270/Q2DZ06Z1 |
More data for this
Ligand-Target Pair | |
Receptor-type tyrosine-protein kinase FLT3
(Homo sapiens (Human)) | BDBM112464
(US8623885, 5)Show SMILES C[C@H]1CC[C@@H](CC1)n1c2cnccc2c2cnc(Nc3ccc4CN(CCc4n3)C(=O)CO)nc12 |r,wU:4.7,wD:1.0,(4.13,-3.21,;3.73,-1.73,;4.82,-.64,;4.42,.85,;2.93,1.25,;1.84,.16,;2.24,-1.33,;2.53,2.74,;3.44,3.98,;4.97,4.14,;5.6,5.55,;4.69,6.8,;3.16,6.64,;2.53,5.23,;1.07,4.75,;-.26,5.52,;-1.6,4.75,;-1.6,3.21,;-2.93,2.44,;-2.93,.9,;-1.6,.13,;-1.6,-1.41,;-2.93,-2.18,;-2.93,-3.72,;-4.26,-4.49,;-5.6,-3.72,;-5.6,-2.18,;-4.26,-1.41,;-4.26,.13,;-4.26,-6.03,;-5.6,-6.8,;-2.93,-6.8,;-1.6,-6.03,;-.26,2.44,;1.07,3.21,)| Show InChI InChI=1S/C26H29N7O2/c1-16-2-5-18(6-3-16)33-22-13-27-10-8-19(22)20-12-28-26(31-25(20)33)30-23-7-4-17-14-32(24(35)15-34)11-9-21(17)29-23/h4,7-8,10,12-13,16,18,34H,2-3,5-6,9,11,14-15H2,1H3,(H,28,29,30,31)/t16-,18- | PDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| Purchase
MCE
PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 1.5 | n/a | n/a | n/a | n/a | 7.6 | n/a |
Amgen Inc.
US Patent
| Assay Description
The FLT3 inhibitory activity of the CDK4/6-FLT3 inhibitors was determined with a HTRF kinase assay. The FLT3 enzyme (GST-FLT3 fusion) was purchased f... |
US Patent US8623885 (2014)
BindingDB Entry DOI: 10.7270/Q2DZ06Z1 |
More data for this
Ligand-Target Pair | |
Receptor-type tyrosine-protein kinase FLT3
(Homo sapiens (Human)) | BDBM112477
(US8623885, 18a)Show SMILES C[C@H]1CC[C@@H](CC1)n1c2cnccc2c2cnc(Nc3ccc4CN(C[C@@H](C)c4n3)C(C)=O)nc12 |r,wU:4.7,26.28,wD:1.0,(4.8,5.44,;4.4,6.93,;5.49,8.02,;5.09,9.51,;3.6,9.91,;2.51,8.82,;2.91,7.33,;3.2,11.39,;4.11,12.64,;5.64,12.8,;6.26,14.21,;5.36,15.45,;3.83,15.29,;3.2,13.89,;1.74,13.41,;.4,14.18,;-.93,13.41,;-.93,11.87,;-2.26,11.1,;-2.26,9.56,;-.93,8.79,;-.93,7.25,;-2.26,6.48,;-2.26,4.94,;-3.6,4.17,;-4.93,4.94,;-4.93,6.48,;-6.26,7.25,;-3.6,7.25,;-3.6,8.79,;-3.6,2.63,;-2.26,1.86,;-4.93,1.86,;.4,11.1,;1.74,11.87,)| Show InChI InChI=1S/C27H31N7O/c1-16-4-7-20(8-5-16)34-23-13-28-11-10-21(23)22-12-29-27(32-26(22)34)31-24-9-6-19-15-33(18(3)35)14-17(2)25(19)30-24/h6,9-13,16-17,20H,4-5,7-8,14-15H2,1-3H3,(H,29,30,31,32)/t16-,17-,20-/m1/s1 | PDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 1.60 | n/a | n/a | n/a | n/a | 7.6 | n/a |
Amgen Inc.
US Patent
| Assay Description
The FLT3 inhibitory activity of the CDK4/6-FLT3 inhibitors was determined with a HTRF kinase assay. The FLT3 enzyme (GST-FLT3 fusion) was purchased f... |
US Patent US8623885 (2014)
BindingDB Entry DOI: 10.7270/Q2DZ06Z1 |
More data for this
Ligand-Target Pair | |
Receptor-type tyrosine-protein kinase FLT3
(Homo sapiens (Human)) | BDBM112469
(US8623885, 10)Show SMILES COCCN1CCc2nc(Nc3ncc4c5ccncc5n([C@H]5CC[C@H](C)CC5)c4n3)ccc2C1 |r,wU:22.22,wD:25.26,(-1.6,-9.11,;-2.93,-8.34,;-2.93,-6.8,;-4.26,-6.03,;-4.26,-4.49,;-5.6,-3.72,;-5.6,-2.18,;-4.26,-1.41,;-4.26,.13,;-2.93,.9,;-2.93,2.44,;-1.6,3.21,;-1.6,4.75,;-.26,5.52,;1.07,4.75,;2.53,5.23,;3.16,6.64,;4.69,6.8,;5.6,5.55,;4.97,4.14,;3.44,3.98,;2.53,2.74,;2.93,1.25,;4.42,.85,;4.82,-.64,;3.73,-1.73,;4.13,-3.21,;2.24,-1.33,;1.84,.16,;1.07,3.21,;-.26,2.44,;-1.6,.13,;-1.6,-1.41,;-2.93,-2.18,;-2.93,-3.72,)| Show InChI InChI=1S/C27H33N7O/c1-18-3-6-20(7-4-18)34-24-16-28-11-9-21(24)22-15-29-27(32-26(22)34)31-25-8-5-19-17-33(13-14-35-2)12-10-23(19)30-25/h5,8-9,11,15-16,18,20H,3-4,6-7,10,12-14,17H2,1-2H3,(H,29,30,31,32)/t18-,20- | PDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 1.70 | n/a | n/a | n/a | n/a | 7.6 | n/a |
Amgen Inc.
US Patent
| Assay Description
The FLT3 inhibitory activity of the CDK4/6-FLT3 inhibitors was determined with a HTRF kinase assay. The FLT3 enzyme (GST-FLT3 fusion) was purchased f... |
US Patent US8623885 (2014)
BindingDB Entry DOI: 10.7270/Q2DZ06Z1 |
More data for this
Ligand-Target Pair | |
Receptor-type tyrosine-protein kinase FLT3
(Homo sapiens (Human)) | BDBM112462
(US8623885, 3)Show SMILES C[C@H]1CC[C@@H](CC1)n1c2cnccc2c2cnc(Nc3ccc4CN(CCO)CCc4n3)nc12 |r,wU:4.7,wD:1.0,(4.13,-3.21,;3.73,-1.73,;4.82,-.64,;4.42,.85,;2.93,1.25,;1.84,.16,;2.24,-1.33,;2.53,2.74,;3.44,3.98,;4.97,4.14,;5.6,5.55,;4.69,6.8,;3.16,6.64,;2.53,5.23,;1.07,4.75,;-.26,5.52,;-1.6,4.75,;-1.6,3.21,;-2.93,2.44,;-2.93,.9,;-1.6,.13,;-1.6,-1.41,;-2.93,-2.18,;-2.93,-3.72,;-4.26,-4.49,;-4.26,-6.03,;-2.93,-6.8,;-1.6,-6.03,;-5.6,-3.72,;-5.6,-2.18,;-4.26,-1.41,;-4.26,.13,;-.26,2.44,;1.07,3.21,)| Show InChI InChI=1S/C26H31N7O/c1-17-2-5-19(6-3-17)33-23-15-27-10-8-20(23)21-14-28-26(31-25(21)33)30-24-7-4-18-16-32(12-13-34)11-9-22(18)29-24/h4,7-8,10,14-15,17,19,34H,2-3,5-6,9,11-13,16H2,1H3,(H,28,29,30,31)/t17-,19- | PDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 1.80 | n/a | n/a | n/a | n/a | 7.6 | n/a |
Amgen Inc.
US Patent
| Assay Description
The FLT3 inhibitory activity of the CDK4/6-FLT3 inhibitors was determined with a HTRF kinase assay. The FLT3 enzyme (GST-FLT3 fusion) was purchased f... |
US Patent US8623885 (2014)
BindingDB Entry DOI: 10.7270/Q2DZ06Z1 |
More data for this
Ligand-Target Pair | |
Receptor-type tyrosine-protein kinase FLT3
(Homo sapiens (Human)) | BDBM112472
(US8623885, 13)Show SMILES C[C@H]1CC[C@@H](CC1)n1c2cnccc2c2cnc(Nc3ccc4CNCC(C)c4n3)nc12 |r,w:26.28,wU:4.7,wD:1.0,(4.8,-4.37,;4.4,-2.88,;5.49,-1.79,;5.09,-.3,;3.6,.09,;2.51,-.99,;2.91,-2.48,;3.2,1.58,;4.11,2.83,;5.64,2.99,;6.26,4.4,;5.36,5.64,;3.83,5.48,;3.2,4.07,;1.74,3.6,;.4,4.37,;-.93,3.6,;-.93,2.06,;-2.26,1.29,;-2.26,-.25,;-.93,-1.02,;-.93,-2.56,;-2.26,-3.33,;-2.26,-4.87,;-3.6,-5.64,;-4.93,-4.87,;-4.93,-3.33,;-6.26,-2.56,;-3.6,-2.56,;-3.6,-1.02,;.4,1.29,;1.74,2.06,)| Show InChI InChI=1S/C25H29N7/c1-15-3-6-18(7-4-15)32-21-14-26-10-9-19(21)20-13-28-25(31-24(20)32)30-22-8-5-17-12-27-11-16(2)23(17)29-22/h5,8-10,13-16,18,27H,3-4,6-7,11-12H2,1-2H3,(H,28,29,30,31)/t15-,16?,18- | PDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 1.80 | n/a | n/a | n/a | n/a | 7.6 | n/a |
Amgen Inc.
US Patent
| Assay Description
The FLT3 inhibitory activity of the CDK4/6-FLT3 inhibitors was determined with a HTRF kinase assay. The FLT3 enzyme (GST-FLT3 fusion) was purchased f... |
US Patent US8623885 (2014)
BindingDB Entry DOI: 10.7270/Q2DZ06Z1 |
More data for this
Ligand-Target Pair | |
Receptor-type tyrosine-protein kinase FLT3
(Homo sapiens (Human)) | BDBM112463
(US8623885, 4)Show SMILES C[C@H]1CC[C@@H](CC1)n1c2cnccc2c2cnc(Nc3ccc4CN(CCCO)CCc4n3)nc12 |r,wU:4.7,wD:1.0,(4.13,-3.21,;3.73,-1.73,;4.82,-.64,;4.42,.85,;2.93,1.25,;1.84,.16,;2.24,-1.33,;2.53,2.74,;3.44,3.98,;4.97,4.14,;5.6,5.55,;4.69,6.8,;3.16,6.64,;2.53,5.23,;1.07,4.75,;-.26,5.52,;-1.6,4.75,;-1.6,3.21,;-2.93,2.44,;-2.93,.9,;-1.6,.13,;-1.6,-1.41,;-2.93,-2.18,;-2.93,-3.72,;-4.26,-4.49,;-4.26,-6.03,;-2.93,-6.8,;-1.6,-6.03,;-.26,-6.8,;-5.6,-3.72,;-5.6,-2.18,;-4.26,-1.41,;-4.26,.13,;-.26,2.44,;1.07,3.21,)| Show InChI InChI=1S/C27H33N7O/c1-18-3-6-20(7-4-18)34-24-16-28-11-9-21(24)22-15-29-27(32-26(22)34)31-25-8-5-19-17-33(12-2-14-35)13-10-23(19)30-25/h5,8-9,11,15-16,18,20,35H,2-4,6-7,10,12-14,17H2,1H3,(H,29,30,31,32)/t18-,20- | PDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 2 | n/a | n/a | n/a | n/a | 7.6 | n/a |
Amgen Inc.
US Patent
| Assay Description
The FLT3 inhibitory activity of the CDK4/6-FLT3 inhibitors was determined with a HTRF kinase assay. The FLT3 enzyme (GST-FLT3 fusion) was purchased f... |
US Patent US8623885 (2014)
BindingDB Entry DOI: 10.7270/Q2DZ06Z1 |
More data for this
Ligand-Target Pair | |
Cyclin-dependent kinase 4
(Homo sapiens (Human)) | BDBM112460
(US8623885, 1)Show SMILES C[C@H]1CC[C@@H](CC1)n1c2cnccc2c2cnc(Nc3ccc4CNCCc4n3)nc12 |r,wU:4.7,wD:1.0,(4.13,-4.37,;3.73,-2.88,;4.82,-1.79,;4.42,-.3,;2.93,.09,;1.84,-.99,;2.24,-2.48,;2.53,1.58,;3.44,2.83,;4.97,2.99,;5.6,4.4,;4.69,5.64,;3.16,5.48,;2.53,4.07,;1.07,3.6,;-.26,4.37,;-1.6,3.6,;-1.6,2.06,;-2.93,1.29,;-2.93,-.25,;-1.6,-1.02,;-1.6,-2.56,;-2.93,-3.33,;-2.93,-4.87,;-4.26,-5.64,;-5.6,-4.87,;-5.6,-3.33,;-4.26,-2.56,;-4.26,-1.02,;-.26,1.29,;1.07,2.06,)| Show InChI InChI=1S/C24H27N7/c1-15-2-5-17(6-3-15)31-21-14-26-10-8-18(21)19-13-27-24(30-23(19)31)29-22-7-4-16-12-25-11-9-20(16)28-22/h4,7-8,10,13-15,17,25H,2-3,5-6,9,11-12H2,1H3,(H,27,28,29,30)/t15-,17- | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 2.10 | n/a | n/a | n/a | n/a | 7.4 | n/a |
Amgen Inc.
US Patent
| Assay Description
The CDK4 and CDK1 inhibitory activity of the CDK4/6-FLT3 inhibitors was determined with a filtration kinase assay. The compounds, kinase and substrat... |
US Patent US8623885 (2014)
BindingDB Entry DOI: 10.7270/Q2DZ06Z1 |
More data for this
Ligand-Target Pair | |
Receptor-type tyrosine-protein kinase FLT3
(Homo sapiens (Human)) | BDBM112497
(US8623885, 18b)Show SMILES C[C@H]1CC[C@@H](CC1)n1c2cnccc2c2cnc(Nc3ccc4CN(C[C@H](C)c4n3)C(C)=O)nc12 |r,wU:4.7,wD:1.0,26.28,(4.8,-11.87,;4.4,-10.38,;5.49,-9.29,;5.09,-7.81,;3.6,-7.41,;2.51,-8.5,;2.91,-9.98,;3.2,-5.92,;4.11,-4.67,;5.64,-4.51,;6.26,-3.11,;5.36,-1.86,;3.83,-2.02,;3.2,-3.43,;1.74,-3.9,;.4,-3.13,;-.93,-3.9,;-.93,-5.44,;-2.26,-6.21,;-2.26,-7.75,;-.93,-8.52,;-.93,-10.06,;-2.26,-10.83,;-2.26,-12.37,;-3.6,-13.14,;-4.93,-12.37,;-4.93,-10.83,;-6.26,-10.06,;-3.6,-10.06,;-3.6,-8.52,;-3.6,-14.68,;-2.26,-15.45,;-4.93,-15.45,;.4,-6.21,;1.74,-5.44,)| Show InChI InChI=1S/C27H31N7O/c1-16-4-7-20(8-5-16)34-23-13-28-11-10-21(23)22-12-29-27(32-26(22)34)31-24-9-6-19-15-33(18(3)35)14-17(2)25(19)30-24/h6,9-13,16-17,20H,4-5,7-8,14-15H2,1-3H3,(H,29,30,31,32)/t16-,17-,20-/m0/s1 | PDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 2.30 | n/a | n/a | n/a | n/a | 7.6 | n/a |
Amgen Inc.
US Patent
| Assay Description
The FLT3 inhibitory activity of the CDK4/6-FLT3 inhibitors was determined with a HTRF kinase assay. The FLT3 enzyme (GST-FLT3 fusion) was purchased f... |
US Patent US8623885 (2014)
BindingDB Entry DOI: 10.7270/Q2DZ06Z1 |
More data for this
Ligand-Target Pair | |
Cyclin-dependent kinase 4
(Homo sapiens (Human)) | BDBM112464
(US8623885, 5)Show SMILES C[C@H]1CC[C@@H](CC1)n1c2cnccc2c2cnc(Nc3ccc4CN(CCc4n3)C(=O)CO)nc12 |r,wU:4.7,wD:1.0,(4.13,-3.21,;3.73,-1.73,;4.82,-.64,;4.42,.85,;2.93,1.25,;1.84,.16,;2.24,-1.33,;2.53,2.74,;3.44,3.98,;4.97,4.14,;5.6,5.55,;4.69,6.8,;3.16,6.64,;2.53,5.23,;1.07,4.75,;-.26,5.52,;-1.6,4.75,;-1.6,3.21,;-2.93,2.44,;-2.93,.9,;-1.6,.13,;-1.6,-1.41,;-2.93,-2.18,;-2.93,-3.72,;-4.26,-4.49,;-5.6,-3.72,;-5.6,-2.18,;-4.26,-1.41,;-4.26,.13,;-4.26,-6.03,;-5.6,-6.8,;-2.93,-6.8,;-1.6,-6.03,;-.26,2.44,;1.07,3.21,)| Show InChI InChI=1S/C26H29N7O2/c1-16-2-5-18(6-3-16)33-22-13-27-10-8-19(22)20-12-28-26(31-25(20)33)30-23-7-4-17-14-32(24(35)15-34)11-9-21(17)29-23/h4,7-8,10,12-13,16,18,34H,2-3,5-6,9,11,14-15H2,1H3,(H,28,29,30,31)/t16-,18- | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| Purchase
MCE
PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 2.40 | n/a | n/a | n/a | n/a | 7.4 | n/a |
Amgen Inc.
US Patent
| Assay Description
The CDK4 and CDK1 inhibitory activity of the CDK4/6-FLT3 inhibitors was determined with a filtration kinase assay. The compounds, kinase and substrat... |
US Patent US8623885 (2014)
BindingDB Entry DOI: 10.7270/Q2DZ06Z1 |
More data for this
Ligand-Target Pair | |
Cyclin-dependent kinase 4
(Homo sapiens (Human)) | BDBM112467
(US8623885, 8)Show SMILES C[C@H]1CC[C@@H](CC1)n1c2cnccc2c2cnc(Nc3ccc4CN(CCS(C)(=O)=O)CCc4n3)nc12 |r,wU:4.7,wD:1.0,(4.13,-3.21,;3.73,-1.73,;4.82,-.64,;4.42,.85,;2.93,1.25,;1.84,.16,;2.24,-1.33,;2.53,2.74,;3.44,3.98,;4.97,4.14,;5.6,5.55,;4.69,6.8,;3.16,6.64,;2.53,5.23,;1.07,4.75,;-.26,5.52,;-1.6,4.75,;-1.6,3.21,;-2.93,2.44,;-2.93,.9,;-1.6,.13,;-1.6,-1.41,;-2.93,-2.18,;-2.93,-3.72,;-4.26,-4.49,;-4.26,-6.03,;-2.93,-6.8,;-1.6,-6.03,;-.26,-6.8,;-2.37,-4.69,;-.83,-4.69,;-5.6,-3.72,;-5.6,-2.18,;-4.26,-1.41,;-4.26,.13,;-.26,2.44,;1.07,3.21,)| Show InChI InChI=1S/C27H33N7O2S/c1-18-3-6-20(7-4-18)34-24-16-28-11-9-21(24)22-15-29-27(32-26(22)34)31-25-8-5-19-17-33(12-10-23(19)30-25)13-14-37(2,35)36/h5,8-9,11,15-16,18,20H,3-4,6-7,10,12-14,17H2,1-2H3,(H,29,30,31,32)/t18-,20- | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 2.40 | n/a | n/a | n/a | n/a | 7.4 | n/a |
Amgen Inc.
US Patent
| Assay Description
The CDK4 and CDK1 inhibitory activity of the CDK4/6-FLT3 inhibitors was determined with a filtration kinase assay. The compounds, kinase and substrat... |
US Patent US8623885 (2014)
BindingDB Entry DOI: 10.7270/Q2DZ06Z1 |
More data for this
Ligand-Target Pair | |
Cyclin-dependent kinase 4
(Homo sapiens (Human)) | BDBM112462
(US8623885, 3)Show SMILES C[C@H]1CC[C@@H](CC1)n1c2cnccc2c2cnc(Nc3ccc4CN(CCO)CCc4n3)nc12 |r,wU:4.7,wD:1.0,(4.13,-3.21,;3.73,-1.73,;4.82,-.64,;4.42,.85,;2.93,1.25,;1.84,.16,;2.24,-1.33,;2.53,2.74,;3.44,3.98,;4.97,4.14,;5.6,5.55,;4.69,6.8,;3.16,6.64,;2.53,5.23,;1.07,4.75,;-.26,5.52,;-1.6,4.75,;-1.6,3.21,;-2.93,2.44,;-2.93,.9,;-1.6,.13,;-1.6,-1.41,;-2.93,-2.18,;-2.93,-3.72,;-4.26,-4.49,;-4.26,-6.03,;-2.93,-6.8,;-1.6,-6.03,;-5.6,-3.72,;-5.6,-2.18,;-4.26,-1.41,;-4.26,.13,;-.26,2.44,;1.07,3.21,)| Show InChI InChI=1S/C26H31N7O/c1-17-2-5-19(6-3-17)33-23-15-27-10-8-20(23)21-14-28-26(31-25(21)33)30-24-7-4-18-16-32(12-13-34)11-9-22(18)29-24/h4,7-8,10,14-15,17,19,34H,2-3,5-6,9,11-13,16H2,1H3,(H,28,29,30,31)/t17-,19- | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 2.60 | n/a | n/a | n/a | n/a | 7.4 | n/a |
Amgen Inc.
US Patent
| Assay Description
The CDK4 and CDK1 inhibitory activity of the CDK4/6-FLT3 inhibitors was determined with a filtration kinase assay. The compounds, kinase and substrat... |
US Patent US8623885 (2014)
BindingDB Entry DOI: 10.7270/Q2DZ06Z1 |
More data for this
Ligand-Target Pair | |
Receptor-type tyrosine-protein kinase FLT3
(Homo sapiens (Human)) | BDBM112471
(US8623885, 12)Show SMILES C[C@H]1CC[C@@H](CC1)n1c2cnccc2c2cnc(Nc3cc4CN(CCO)CCc4cn3)nc12 |r,wU:4.7,wD:1.0,(3.46,-3.21,;3.06,-1.73,;4.15,-.64,;3.75,.85,;2.27,1.25,;1.18,.16,;1.58,-1.33,;1.87,2.74,;2.77,3.98,;4.3,4.14,;4.93,5.55,;4.03,6.8,;2.49,6.64,;1.87,5.23,;.4,4.75,;-.93,5.52,;-2.26,4.75,;-2.26,3.21,;-3.6,2.44,;-3.6,.9,;-2.26,.13,;-2.26,-1.41,;-.93,-2.18,;-.93,-3.72,;.4,-4.49,;.4,-6.03,;1.74,-6.8,;-2.26,-4.49,;-3.6,-3.72,;-3.6,-2.18,;-4.93,-1.41,;-4.93,.13,;-.93,2.44,;.4,3.21,)| Show InChI InChI=1S/C26H31N7O/c1-17-2-4-20(5-3-17)33-23-15-27-8-6-21(23)22-14-29-26(31-25(22)33)30-24-12-19-16-32(10-11-34)9-7-18(19)13-28-24/h6,8,12-15,17,20,34H,2-5,7,9-11,16H2,1H3,(H,28,29,30,31)/t17-,20- | PDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 2.70 | n/a | n/a | n/a | n/a | 7.6 | n/a |
Amgen Inc.
US Patent
| Assay Description
The FLT3 inhibitory activity of the CDK4/6-FLT3 inhibitors was determined with a HTRF kinase assay. The FLT3 enzyme (GST-FLT3 fusion) was purchased f... |
US Patent US8623885 (2014)
BindingDB Entry DOI: 10.7270/Q2DZ06Z1 |
More data for this
Ligand-Target Pair | |
Receptor-type tyrosine-protein kinase FLT3
(Homo sapiens (Human)) | BDBM112476
(US8623885, 17)Show SMILES C[C@H]1CC[C@@H](CC1)n1c2cnccc2c2cnc(Nc3ccc4CN(CCO)CC(O)c4n3)nc12 |r,w:29.31,wU:4.7,wD:1.0,(4.8,-3.21,;4.4,-1.73,;5.49,-.64,;5.09,.85,;3.6,1.25,;2.51,.16,;2.91,-1.33,;3.2,2.74,;4.11,3.98,;5.64,4.14,;6.26,5.55,;5.36,6.8,;3.83,6.64,;3.2,5.23,;1.74,4.75,;.4,5.52,;-.93,4.75,;-.93,3.21,;-2.26,2.44,;-2.26,.9,;-.93,.13,;-.93,-1.41,;-2.26,-2.18,;-2.26,-3.72,;-3.6,-4.49,;-3.6,-6.03,;-2.26,-6.8,;-.93,-6.03,;-4.93,-3.72,;-4.93,-2.18,;-6.26,-1.41,;-3.6,-1.41,;-3.6,.13,;.4,2.44,;1.74,3.21,)| Show InChI InChI=1S/C26H31N7O2/c1-16-2-5-18(6-3-16)33-21-13-27-9-8-19(21)20-12-28-26(31-25(20)33)30-23-7-4-17-14-32(10-11-34)15-22(35)24(17)29-23/h4,7-9,12-13,16,18,22,34-35H,2-3,5-6,10-11,14-15H2,1H3,(H,28,29,30,31)/t16-,18-,22? | PDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 2.90 | n/a | n/a | n/a | n/a | 7.6 | n/a |
Amgen Inc.
US Patent
| Assay Description
The FLT3 inhibitory activity of the CDK4/6-FLT3 inhibitors was determined with a HTRF kinase assay. The FLT3 enzyme (GST-FLT3 fusion) was purchased f... |
US Patent US8623885 (2014)
BindingDB Entry DOI: 10.7270/Q2DZ06Z1 |
More data for this
Ligand-Target Pair | |
Cyclin-dependent kinase 4
(Homo sapiens (Human)) | BDBM112496
(US8623885, 37)Show SMILES CCN(CC)CC(=O)N1CCc2nc(Nc3ncc4c5ccncc5n([C@H]5CC[C@H](C)CC5)c4n3)ccc2C1 |r,wU:26.26,wD:29.30,(-.26,-2.95,;-1.6,-3.72,;-1.6,-5.26,;-.26,-6.03,;-.26,-7.57,;-2.93,-6.03,;-4.26,-5.26,;-5.6,-6.03,;-4.26,-3.72,;-5.6,-2.95,;-5.6,-1.41,;-4.26,-.64,;-4.26,.9,;-2.93,1.67,;-2.93,3.21,;-1.6,3.98,;-1.6,5.52,;-.26,6.29,;1.07,5.52,;2.53,6,;3.16,7.41,;4.69,7.57,;5.6,6.32,;4.97,4.91,;3.44,4.75,;2.53,3.51,;2.93,2.02,;4.42,1.62,;4.82,.13,;3.73,-.96,;4.13,-2.44,;2.24,-.56,;1.84,.93,;1.07,3.98,;-.26,3.21,;-1.6,.9,;-1.6,-.64,;-2.93,-1.41,;-2.93,-2.95,)| Show InChI InChI=1S/C30H38N8O/c1-4-36(5-2)19-28(39)37-15-13-25-21(18-37)8-11-27(33-25)34-30-32-16-24-23-12-14-31-17-26(23)38(29(24)35-30)22-9-6-20(3)7-10-22/h8,11-12,14,16-17,20,22H,4-7,9-10,13,15,18-19H2,1-3H3,(H,32,33,34,35)/t20-,22- | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 3 | n/a | n/a | n/a | n/a | 7.4 | n/a |
Amgen Inc.
US Patent
| Assay Description
The CDK4 and CDK1 inhibitory activity of the CDK4/6-FLT3 inhibitors was determined with a filtration kinase assay. The compounds, kinase and substrat... |
US Patent US8623885 (2014)
BindingDB Entry DOI: 10.7270/Q2DZ06Z1 |
More data for this
Ligand-Target Pair | |
Receptor-type tyrosine-protein kinase FLT3
(Homo sapiens (Human)) | BDBM112474
(US8623885, 15)Show SMILES C[C@H]1CC[C@@H](CC1)n1c2cnccc2c2cnc(Nc3ccc4CN(CCO)CC(C)c4n3)nc12 |r,w:29.31,wU:4.7,wD:1.0,(4.8,-3.21,;4.4,-1.73,;5.49,-.64,;5.09,.85,;3.6,1.25,;2.51,.16,;2.91,-1.33,;3.2,2.74,;4.11,3.98,;5.64,4.14,;6.26,5.55,;5.36,6.8,;3.83,6.64,;3.2,5.23,;1.74,4.75,;.4,5.52,;-.93,4.75,;-.93,3.21,;-2.26,2.44,;-2.26,.9,;-.93,.13,;-.93,-1.41,;-2.26,-2.18,;-2.26,-3.72,;-3.6,-4.49,;-3.6,-6.03,;-2.26,-6.8,;-.93,-6.03,;-4.93,-3.72,;-4.93,-2.18,;-6.26,-1.41,;-3.6,-1.41,;-3.6,.13,;.4,2.44,;1.74,3.21,)| Show InChI InChI=1S/C27H33N7O/c1-17-3-6-20(7-4-17)34-23-14-28-10-9-21(23)22-13-29-27(32-26(22)34)31-24-8-5-19-16-33(11-12-35)15-18(2)25(19)30-24/h5,8-10,13-14,17-18,20,35H,3-4,6-7,11-12,15-16H2,1-2H3,(H,29,30,31,32)/t17-,18?,20- | PDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 3.10 | n/a | n/a | n/a | n/a | 7.6 | n/a |
Amgen Inc.
US Patent
| Assay Description
The FLT3 inhibitory activity of the CDK4/6-FLT3 inhibitors was determined with a HTRF kinase assay. The FLT3 enzyme (GST-FLT3 fusion) was purchased f... |
US Patent US8623885 (2014)
BindingDB Entry DOI: 10.7270/Q2DZ06Z1 |
More data for this
Ligand-Target Pair | |
Receptor-type tyrosine-protein kinase FLT3
(Homo sapiens (Human)) | BDBM112461
(US8623885, 2)Show SMILES C[C@H]1CC[C@@H](CC1)n1c2cnccc2c2cnc(Nc3ccc4CN(CCc4n3)C(C)=O)nc12 |r,wU:4.7,wD:1.0,(4.13,-3.21,;3.73,-1.73,;4.82,-.64,;4.42,.85,;2.93,1.25,;1.84,.16,;2.24,-1.33,;2.53,2.74,;3.44,3.98,;4.97,4.14,;5.6,5.55,;4.69,6.8,;3.16,6.64,;2.53,5.23,;1.07,4.75,;-.26,5.52,;-1.6,4.75,;-1.6,3.21,;-2.93,2.44,;-2.93,.9,;-1.6,.13,;-1.6,-1.41,;-2.93,-2.18,;-2.93,-3.72,;-4.26,-4.49,;-5.6,-3.72,;-5.6,-2.18,;-4.26,-1.41,;-4.26,.13,;-4.26,-6.03,;-2.93,-6.8,;-5.6,-6.8,;-.26,2.44,;1.07,3.21,)| Show InChI InChI=1S/C26H29N7O/c1-16-3-6-19(7-4-16)33-23-14-27-11-9-20(23)21-13-28-26(31-25(21)33)30-24-8-5-18-15-32(17(2)34)12-10-22(18)29-24/h5,8-9,11,13-14,16,19H,3-4,6-7,10,12,15H2,1-2H3,(H,28,29,30,31)/t16-,19- | PDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 3.20 | n/a | n/a | n/a | n/a | 7.6 | n/a |
Amgen Inc.
US Patent
| Assay Description
The FLT3 inhibitory activity of the CDK4/6-FLT3 inhibitors was determined with a HTRF kinase assay. The FLT3 enzyme (GST-FLT3 fusion) was purchased f... |
US Patent US8623885 (2014)
BindingDB Entry DOI: 10.7270/Q2DZ06Z1 |
More data for this
Ligand-Target Pair | |
Receptor-type tyrosine-protein kinase FLT3
(Homo sapiens (Human)) | BDBM112473
(US8623885, 14)Show SMILES C[C@H]1CC[C@@H](CC1)n1c2cnccc2c2cnc(Nc3ccc4CN(CC(C)c4n3)C(C)=O)nc12 |r,w:26.28,wU:4.7,wD:1.0,(4.8,-3.21,;4.4,-1.73,;5.49,-.64,;5.09,.85,;3.6,1.25,;2.51,.16,;2.91,-1.33,;3.2,2.74,;4.11,3.98,;5.64,4.14,;6.26,5.55,;5.36,6.8,;3.83,6.64,;3.2,5.23,;1.74,4.75,;.4,5.52,;-.93,4.75,;-.93,3.21,;-2.26,2.44,;-2.26,.9,;-.93,.13,;-.93,-1.41,;-2.26,-2.18,;-2.26,-3.72,;-3.6,-4.49,;-4.93,-3.72,;-4.93,-2.18,;-6.26,-1.41,;-3.6,-1.41,;-3.6,.13,;-3.6,-6.03,;-2.26,-6.8,;-4.93,-6.8,;.4,2.44,;1.74,3.21,)| Show InChI InChI=1S/C27H31N7O/c1-16-4-7-20(8-5-16)34-23-13-28-11-10-21(23)22-12-29-27(32-26(22)34)31-24-9-6-19-15-33(18(3)35)14-17(2)25(19)30-24/h6,9-13,16-17,20H,4-5,7-8,14-15H2,1-3H3,(H,29,30,31,32)/t16-,17?,20- | PDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 3.20 | n/a | n/a | n/a | n/a | 7.6 | n/a |
Amgen Inc.
US Patent
| Assay Description
The FLT3 inhibitory activity of the CDK4/6-FLT3 inhibitors was determined with a HTRF kinase assay. The FLT3 enzyme (GST-FLT3 fusion) was purchased f... |
US Patent US8623885 (2014)
BindingDB Entry DOI: 10.7270/Q2DZ06Z1 |
More data for this
Ligand-Target Pair | |
Receptor-type tyrosine-protein kinase FLT3
(Homo sapiens (Human)) | BDBM112465
(US8623885, 6)Show SMILES C[C@H]1CC[C@@H](CC1)n1c2cnccc2c2cnc(Nc3ccc4CN(CCc4n3)C(=O)C(O)=O)nc12 |r,wU:4.7,wD:1.0,(4.13,-2.44,;3.73,-.96,;4.82,.13,;4.42,1.62,;2.93,2.02,;1.84,.93,;2.24,-.56,;2.53,3.51,;3.44,4.75,;4.97,4.91,;5.6,6.32,;4.69,7.57,;3.16,7.41,;2.53,6,;1.07,5.52,;-.26,6.29,;-1.6,5.52,;-1.6,3.98,;-2.93,3.21,;-2.93,1.67,;-1.6,.9,;-1.6,-.64,;-2.93,-1.41,;-2.93,-2.95,;-4.26,-3.72,;-5.6,-2.95,;-5.6,-1.41,;-4.26,-.64,;-4.26,.9,;-4.26,-5.26,;-5.6,-6.03,;-2.93,-6.03,;-1.6,-5.26,;-2.93,-7.57,;-.26,3.21,;1.07,3.98,)| Show InChI InChI=1S/C26H27N7O3/c1-15-2-5-17(6-3-15)33-21-13-27-10-8-18(21)19-12-28-26(31-23(19)33)30-22-7-4-16-14-32(24(34)25(35)36)11-9-20(16)29-22/h4,7-8,10,12-13,15,17H,2-3,5-6,9,11,14H2,1H3,(H,35,36)(H,28,29,30,31)/t15-,17- | PDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 3.30 | n/a | n/a | n/a | n/a | 7.6 | n/a |
Amgen Inc.
US Patent
| Assay Description
The FLT3 inhibitory activity of the CDK4/6-FLT3 inhibitors was determined with a HTRF kinase assay. The FLT3 enzyme (GST-FLT3 fusion) was purchased f... |
US Patent US8623885 (2014)
BindingDB Entry DOI: 10.7270/Q2DZ06Z1 |
More data for this
Ligand-Target Pair | |
Receptor-type tyrosine-protein kinase FLT3
(Homo sapiens (Human)) | BDBM112468
(US8623885, 9)Show SMILES C[C@H]1CC[C@@H](CC1)n1c2cnccc2c2cnc(Nc3ccc4CN(CCF)CCc4n3)nc12 |r,wU:4.7,wD:1.0,(4.13,-3.21,;3.73,-1.73,;4.82,-.64,;4.42,.85,;2.93,1.25,;1.84,.16,;2.24,-1.33,;2.53,2.74,;3.44,3.98,;4.97,4.14,;5.6,5.55,;4.69,6.8,;3.16,6.64,;2.53,5.23,;1.07,4.75,;-.26,5.52,;-1.6,4.75,;-1.6,3.21,;-2.93,2.44,;-2.93,.9,;-1.6,.13,;-1.6,-1.41,;-2.93,-2.18,;-2.93,-3.72,;-4.26,-4.49,;-4.26,-6.03,;-2.93,-6.8,;-1.6,-6.03,;-5.6,-3.72,;-5.6,-2.18,;-4.26,-1.41,;-4.26,.13,;-.26,2.44,;1.07,3.21,)| Show InChI InChI=1S/C26H30FN7/c1-17-2-5-19(6-3-17)34-23-15-28-11-8-20(23)21-14-29-26(32-25(21)34)31-24-7-4-18-16-33(13-10-27)12-9-22(18)30-24/h4,7-8,11,14-15,17,19H,2-3,5-6,9-10,12-13,16H2,1H3,(H,29,30,31,32)/t17-,19- | PDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 3.40 | n/a | n/a | n/a | n/a | 7.6 | n/a |
Amgen Inc.
US Patent
| Assay Description
The FLT3 inhibitory activity of the CDK4/6-FLT3 inhibitors was determined with a HTRF kinase assay. The FLT3 enzyme (GST-FLT3 fusion) was purchased f... |
US Patent US8623885 (2014)
BindingDB Entry DOI: 10.7270/Q2DZ06Z1 |
More data for this
Ligand-Target Pair | |
Cyclin-dependent kinase 4
(Homo sapiens (Human)) | BDBM112473
(US8623885, 14)Show SMILES C[C@H]1CC[C@@H](CC1)n1c2cnccc2c2cnc(Nc3ccc4CN(CC(C)c4n3)C(C)=O)nc12 |r,w:26.28,wU:4.7,wD:1.0,(4.8,-3.21,;4.4,-1.73,;5.49,-.64,;5.09,.85,;3.6,1.25,;2.51,.16,;2.91,-1.33,;3.2,2.74,;4.11,3.98,;5.64,4.14,;6.26,5.55,;5.36,6.8,;3.83,6.64,;3.2,5.23,;1.74,4.75,;.4,5.52,;-.93,4.75,;-.93,3.21,;-2.26,2.44,;-2.26,.9,;-.93,.13,;-.93,-1.41,;-2.26,-2.18,;-2.26,-3.72,;-3.6,-4.49,;-4.93,-3.72,;-4.93,-2.18,;-6.26,-1.41,;-3.6,-1.41,;-3.6,.13,;-3.6,-6.03,;-2.26,-6.8,;-4.93,-6.8,;.4,2.44,;1.74,3.21,)| Show InChI InChI=1S/C27H31N7O/c1-16-4-7-20(8-5-16)34-23-13-28-11-10-21(23)22-12-29-27(32-26(22)34)31-24-9-6-19-15-33(18(3)35)14-17(2)25(19)30-24/h6,9-13,16-17,20H,4-5,7-8,14-15H2,1-3H3,(H,29,30,31,32)/t16-,17?,20- | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 4.40 | n/a | n/a | n/a | n/a | 7.4 | n/a |
Amgen Inc.
US Patent
| Assay Description
The CDK4 and CDK1 inhibitory activity of the CDK4/6-FLT3 inhibitors was determined with a filtration kinase assay. The compounds, kinase and substrat... |
US Patent US8623885 (2014)
BindingDB Entry DOI: 10.7270/Q2DZ06Z1 |
More data for this
Ligand-Target Pair | |
Cyclin-dependent kinase 4
(Homo sapiens (Human)) | BDBM112461
(US8623885, 2)Show SMILES C[C@H]1CC[C@@H](CC1)n1c2cnccc2c2cnc(Nc3ccc4CN(CCc4n3)C(C)=O)nc12 |r,wU:4.7,wD:1.0,(4.13,-3.21,;3.73,-1.73,;4.82,-.64,;4.42,.85,;2.93,1.25,;1.84,.16,;2.24,-1.33,;2.53,2.74,;3.44,3.98,;4.97,4.14,;5.6,5.55,;4.69,6.8,;3.16,6.64,;2.53,5.23,;1.07,4.75,;-.26,5.52,;-1.6,4.75,;-1.6,3.21,;-2.93,2.44,;-2.93,.9,;-1.6,.13,;-1.6,-1.41,;-2.93,-2.18,;-2.93,-3.72,;-4.26,-4.49,;-5.6,-3.72,;-5.6,-2.18,;-4.26,-1.41,;-4.26,.13,;-4.26,-6.03,;-2.93,-6.8,;-5.6,-6.8,;-.26,2.44,;1.07,3.21,)| Show InChI InChI=1S/C26H29N7O/c1-16-3-6-19(7-4-16)33-23-14-27-11-9-20(23)21-13-28-26(31-25(21)33)30-24-8-5-18-15-32(17(2)34)12-10-22(18)29-24/h5,8-9,11,13-14,16,19H,3-4,6-7,10,12,15H2,1-2H3,(H,28,29,30,31)/t16-,19- | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 4.5 | n/a | n/a | n/a | n/a | 7.4 | n/a |
Amgen Inc.
US Patent
| Assay Description
The CDK4 and CDK1 inhibitory activity of the CDK4/6-FLT3 inhibitors was determined with a filtration kinase assay. The compounds, kinase and substrat... |
US Patent US8623885 (2014)
BindingDB Entry DOI: 10.7270/Q2DZ06Z1 |
More data for this
Ligand-Target Pair | |
Cyclin-dependent kinase 4
(Homo sapiens (Human)) | BDBM112463
(US8623885, 4)Show SMILES C[C@H]1CC[C@@H](CC1)n1c2cnccc2c2cnc(Nc3ccc4CN(CCCO)CCc4n3)nc12 |r,wU:4.7,wD:1.0,(4.13,-3.21,;3.73,-1.73,;4.82,-.64,;4.42,.85,;2.93,1.25,;1.84,.16,;2.24,-1.33,;2.53,2.74,;3.44,3.98,;4.97,4.14,;5.6,5.55,;4.69,6.8,;3.16,6.64,;2.53,5.23,;1.07,4.75,;-.26,5.52,;-1.6,4.75,;-1.6,3.21,;-2.93,2.44,;-2.93,.9,;-1.6,.13,;-1.6,-1.41,;-2.93,-2.18,;-2.93,-3.72,;-4.26,-4.49,;-4.26,-6.03,;-2.93,-6.8,;-1.6,-6.03,;-.26,-6.8,;-5.6,-3.72,;-5.6,-2.18,;-4.26,-1.41,;-4.26,.13,;-.26,2.44,;1.07,3.21,)| Show InChI InChI=1S/C27H33N7O/c1-18-3-6-20(7-4-18)34-24-16-28-11-9-21(24)22-15-29-27(32-26(22)34)31-25-8-5-19-17-33(12-2-14-35)13-10-23(19)30-25/h5,8-9,11,15-16,18,20,35H,2-4,6-7,10,12-14,17H2,1H3,(H,29,30,31,32)/t18-,20- | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 4.60 | n/a | n/a | n/a | n/a | 7.4 | n/a |
Amgen Inc.
US Patent
| Assay Description
The CDK4 and CDK1 inhibitory activity of the CDK4/6-FLT3 inhibitors was determined with a filtration kinase assay. The compounds, kinase and substrat... |
US Patent US8623885 (2014)
BindingDB Entry DOI: 10.7270/Q2DZ06Z1 |
More data for this
Ligand-Target Pair | |
Cyclin-dependent kinase 4
(Homo sapiens (Human)) | BDBM112483
(US8623885, 24)Show SMILES C[C@H]1CC[C@@H](CC1)n1c2cnccc2c2cnc(Nc3cc4CCNCc4cn3)nc12 |r,wU:4.7,wD:1.0,(3.46,-4.37,;3.06,-2.88,;4.15,-1.79,;3.75,-.3,;2.27,.09,;1.18,-.99,;1.58,-2.48,;1.87,1.58,;2.77,2.83,;4.3,2.99,;4.93,4.4,;4.03,5.64,;2.49,5.48,;1.87,4.07,;.4,3.6,;-.93,4.37,;-2.26,3.6,;-2.26,2.06,;-3.6,1.29,;-3.6,-.25,;-2.26,-1.02,;-2.26,-2.56,;-.93,-3.33,;-.93,-4.87,;-2.26,-5.64,;-3.6,-4.87,;-3.6,-3.33,;-4.93,-2.56,;-4.93,-1.02,;-.93,1.29,;.4,2.06,)| Show InChI InChI=1S/C24H27N7/c1-15-2-4-18(5-3-15)31-21-14-26-9-7-19(21)20-13-28-24(30-23(20)31)29-22-10-16-6-8-25-11-17(16)12-27-22/h7,9-10,12-15,18,25H,2-6,8,11H2,1H3,(H,27,28,29,30)/t15-,18- | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 4.70 | n/a | n/a | n/a | n/a | 7.4 | n/a |
Amgen Inc.
US Patent
| Assay Description
The CDK4 and CDK1 inhibitory activity of the CDK4/6-FLT3 inhibitors was determined with a filtration kinase assay. The compounds, kinase and substrat... |
US Patent US8623885 (2014)
BindingDB Entry DOI: 10.7270/Q2DZ06Z1 |
More data for this
Ligand-Target Pair | |
Cyclin-dependent kinase 4
(Homo sapiens (Human)) | BDBM112489
(US8623885, 30)Show SMILES C[C@H]1CC[C@@H](CC1)n1c2cnccc2c2cnc(Nc3ccc4CCN(Cc4n3)C(=O)CO)nc12 |r,wU:4.7,wD:1.0,(6.13,-3.6,;5.73,-2.11,;6.82,-1.02,;6.42,.47,;4.93,.86,;3.85,-.22,;4.24,-1.71,;4.54,2.35,;5.44,3.6,;6.97,3.76,;7.6,5.17,;6.69,6.41,;5.16,6.25,;4.54,4.84,;3.07,4.37,;1.74,5.14,;.4,4.37,;.4,2.83,;-.93,2.06,;-.93,.52,;.4,-.25,;.4,-1.79,;-.93,-2.56,;-.93,-4.1,;-2.26,-4.87,;-3.6,-4.1,;-3.6,-2.56,;-2.26,-1.79,;-2.26,-.25,;-4.93,-4.87,;-4.93,-6.41,;-6.26,-4.1,;-7.6,-4.87,;1.74,2.06,;3.07,2.83,)| Show InChI InChI=1S/C26H29N7O2/c1-16-2-5-18(6-3-16)33-22-13-27-10-8-19(22)20-12-28-26(31-25(20)33)30-23-7-4-17-9-11-32(24(35)15-34)14-21(17)29-23/h4,7-8,10,12-13,16,18,34H,2-3,5-6,9,11,14-15H2,1H3,(H,28,29,30,31)/t16-,18- | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 6.30 | n/a | n/a | n/a | n/a | 7.4 | n/a |
Amgen Inc.
US Patent
| Assay Description
The CDK4 and CDK1 inhibitory activity of the CDK4/6-FLT3 inhibitors was determined with a filtration kinase assay. The compounds, kinase and substrat... |
US Patent US8623885 (2014)
BindingDB Entry DOI: 10.7270/Q2DZ06Z1 |
More data for this
Ligand-Target Pair | |
Cyclin-dependent kinase 4
(Homo sapiens (Human)) | BDBM112482
(US8623885, 23)Show SMILES C[C@H]1CC[C@@H](CC1)n1c2cnccc2c2cnc(Nc3ccc4CCNCc4n3)nc12 |r,wU:4.7,wD:1.0,(4.13,-4.37,;3.73,-2.88,;4.82,-1.79,;4.42,-.3,;2.93,.09,;1.84,-.99,;2.24,-2.48,;2.53,1.58,;3.44,2.83,;4.97,2.99,;5.6,4.4,;4.69,5.64,;3.16,5.48,;2.53,4.07,;1.07,3.6,;-.26,4.37,;-1.6,3.6,;-1.6,2.06,;-2.93,1.29,;-2.93,-.25,;-1.6,-1.02,;-1.6,-2.56,;-2.93,-3.33,;-2.93,-4.87,;-4.26,-5.64,;-5.6,-4.87,;-5.6,-3.33,;-4.26,-2.56,;-4.26,-1.02,;-.26,1.29,;1.07,2.06,)| Show InChI InChI=1S/C24H27N7/c1-15-2-5-17(6-3-15)31-21-14-26-11-9-18(21)19-12-27-24(30-23(19)31)29-22-7-4-16-8-10-25-13-20(16)28-22/h4,7,9,11-12,14-15,17,25H,2-3,5-6,8,10,13H2,1H3,(H,27,28,29,30)/t15-,17- | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 8.60 | n/a | n/a | n/a | n/a | 7.4 | n/a |
Amgen Inc.
US Patent
| Assay Description
The CDK4 and CDK1 inhibitory activity of the CDK4/6-FLT3 inhibitors was determined with a filtration kinase assay. The compounds, kinase and substrat... |
US Patent US8623885 (2014)
BindingDB Entry DOI: 10.7270/Q2DZ06Z1 |
More data for this
Ligand-Target Pair | |
Cyclin-dependent kinase 4
(Homo sapiens (Human)) | BDBM112469
(US8623885, 10)Show SMILES COCCN1CCc2nc(Nc3ncc4c5ccncc5n([C@H]5CC[C@H](C)CC5)c4n3)ccc2C1 |r,wU:22.22,wD:25.26,(-1.6,-9.11,;-2.93,-8.34,;-2.93,-6.8,;-4.26,-6.03,;-4.26,-4.49,;-5.6,-3.72,;-5.6,-2.18,;-4.26,-1.41,;-4.26,.13,;-2.93,.9,;-2.93,2.44,;-1.6,3.21,;-1.6,4.75,;-.26,5.52,;1.07,4.75,;2.53,5.23,;3.16,6.64,;4.69,6.8,;5.6,5.55,;4.97,4.14,;3.44,3.98,;2.53,2.74,;2.93,1.25,;4.42,.85,;4.82,-.64,;3.73,-1.73,;4.13,-3.21,;2.24,-1.33,;1.84,.16,;1.07,3.21,;-.26,2.44,;-1.6,.13,;-1.6,-1.41,;-2.93,-2.18,;-2.93,-3.72,)| Show InChI InChI=1S/C27H33N7O/c1-18-3-6-20(7-4-18)34-24-16-28-11-9-21(24)22-15-29-27(32-26(22)34)31-25-8-5-19-17-33(13-14-35-2)12-10-23(19)30-25/h5,8-9,11,15-16,18,20H,3-4,6-7,10,12-14,17H2,1-2H3,(H,29,30,31,32)/t18-,20- | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 10.5 | n/a | n/a | n/a | n/a | 7.4 | n/a |
Amgen Inc.
US Patent
| Assay Description
The CDK4 and CDK1 inhibitory activity of the CDK4/6-FLT3 inhibitors was determined with a filtration kinase assay. The compounds, kinase and substrat... |
US Patent US8623885 (2014)
BindingDB Entry DOI: 10.7270/Q2DZ06Z1 |
More data for this
Ligand-Target Pair | |
Cyclin-dependent kinase 4
(Homo sapiens (Human)) | BDBM112475
(US8623885, 16)Show SMILES C[C@H]1CC[C@@H](CC1)n1c2cnccc2c2cnc(Nc3ccc4CNCC(O)c4n3)nc12 |r,w:26.28,wU:4.7,wD:1.0,(4.8,-4.37,;4.4,-2.88,;5.49,-1.79,;5.09,-.3,;3.6,.09,;2.51,-.99,;2.91,-2.48,;3.2,1.58,;4.11,2.83,;5.64,2.99,;6.26,4.4,;5.36,5.64,;3.83,5.48,;3.2,4.07,;1.74,3.6,;.4,4.37,;-.93,3.6,;-.93,2.06,;-2.26,1.29,;-2.26,-.25,;-.93,-1.02,;-.93,-2.56,;-2.26,-3.33,;-2.26,-4.87,;-3.6,-5.64,;-4.93,-4.87,;-4.93,-3.33,;-6.26,-2.56,;-3.6,-2.56,;-3.6,-1.02,;.4,1.29,;1.74,2.06,)| Show InChI InChI=1S/C24H27N7O/c1-14-2-5-16(6-3-14)31-19-12-25-9-8-17(19)18-11-27-24(30-23(18)31)29-21-7-4-15-10-26-13-20(32)22(15)28-21/h4,7-9,11-12,14,16,20,26,32H,2-3,5-6,10,13H2,1H3,(H,27,28,29,30)/t14-,16-,20? | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 16.5 | n/a | n/a | n/a | n/a | 7.4 | n/a |
Amgen Inc.
US Patent
| Assay Description
The CDK4 and CDK1 inhibitory activity of the CDK4/6-FLT3 inhibitors was determined with a filtration kinase assay. The compounds, kinase and substrat... |
US Patent US8623885 (2014)
BindingDB Entry DOI: 10.7270/Q2DZ06Z1 |
More data for this
Ligand-Target Pair | |
Cyclin-dependent kinase 4
(Homo sapiens (Human)) | BDBM112471
(US8623885, 12)Show SMILES C[C@H]1CC[C@@H](CC1)n1c2cnccc2c2cnc(Nc3cc4CN(CCO)CCc4cn3)nc12 |r,wU:4.7,wD:1.0,(3.46,-3.21,;3.06,-1.73,;4.15,-.64,;3.75,.85,;2.27,1.25,;1.18,.16,;1.58,-1.33,;1.87,2.74,;2.77,3.98,;4.3,4.14,;4.93,5.55,;4.03,6.8,;2.49,6.64,;1.87,5.23,;.4,4.75,;-.93,5.52,;-2.26,4.75,;-2.26,3.21,;-3.6,2.44,;-3.6,.9,;-2.26,.13,;-2.26,-1.41,;-.93,-2.18,;-.93,-3.72,;.4,-4.49,;.4,-6.03,;1.74,-6.8,;-2.26,-4.49,;-3.6,-3.72,;-3.6,-2.18,;-4.93,-1.41,;-4.93,.13,;-.93,2.44,;.4,3.21,)| Show InChI InChI=1S/C26H31N7O/c1-17-2-4-20(5-3-17)33-23-15-27-8-6-21(23)22-14-29-26(31-25(22)33)30-24-12-19-16-32(10-11-34)9-7-18(19)13-28-24/h6,8,12-15,17,20,34H,2-5,7,9-11,16H2,1H3,(H,28,29,30,31)/t17-,20- | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 18.4 | n/a | n/a | n/a | n/a | 7.4 | n/a |
Amgen Inc.
US Patent
| Assay Description
The CDK4 and CDK1 inhibitory activity of the CDK4/6-FLT3 inhibitors was determined with a filtration kinase assay. The compounds, kinase and substrat... |
US Patent US8623885 (2014)
BindingDB Entry DOI: 10.7270/Q2DZ06Z1 |
More data for this
Ligand-Target Pair | |
Cyclin-dependent kinase 4
(Homo sapiens (Human)) | BDBM112477
(US8623885, 18a)Show SMILES C[C@H]1CC[C@@H](CC1)n1c2cnccc2c2cnc(Nc3ccc4CN(C[C@@H](C)c4n3)C(C)=O)nc12 |r,wU:4.7,26.28,wD:1.0,(4.8,5.44,;4.4,6.93,;5.49,8.02,;5.09,9.51,;3.6,9.91,;2.51,8.82,;2.91,7.33,;3.2,11.39,;4.11,12.64,;5.64,12.8,;6.26,14.21,;5.36,15.45,;3.83,15.29,;3.2,13.89,;1.74,13.41,;.4,14.18,;-.93,13.41,;-.93,11.87,;-2.26,11.1,;-2.26,9.56,;-.93,8.79,;-.93,7.25,;-2.26,6.48,;-2.26,4.94,;-3.6,4.17,;-4.93,4.94,;-4.93,6.48,;-6.26,7.25,;-3.6,7.25,;-3.6,8.79,;-3.6,2.63,;-2.26,1.86,;-4.93,1.86,;.4,11.1,;1.74,11.87,)| Show InChI InChI=1S/C27H31N7O/c1-16-4-7-20(8-5-16)34-23-13-28-11-10-21(23)22-12-29-27(32-26(22)34)31-24-9-6-19-15-33(18(3)35)14-17(2)25(19)30-24/h6,9-13,16-17,20H,4-5,7-8,14-15H2,1-3H3,(H,29,30,31,32)/t16-,17-,20-/m1/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 18.8 | n/a | n/a | n/a | n/a | 7.4 | n/a |
Amgen Inc.
US Patent
| Assay Description
The CDK4 and CDK1 inhibitory activity of the CDK4/6-FLT3 inhibitors was determined with a filtration kinase assay. The compounds, kinase and substrat... |
US Patent US8623885 (2014)
BindingDB Entry DOI: 10.7270/Q2DZ06Z1 |
More data for this
Ligand-Target Pair | |
Cyclin-dependent kinase 4
(Homo sapiens (Human)) | BDBM112476
(US8623885, 17)Show SMILES C[C@H]1CC[C@@H](CC1)n1c2cnccc2c2cnc(Nc3ccc4CN(CCO)CC(O)c4n3)nc12 |r,w:29.31,wU:4.7,wD:1.0,(4.8,-3.21,;4.4,-1.73,;5.49,-.64,;5.09,.85,;3.6,1.25,;2.51,.16,;2.91,-1.33,;3.2,2.74,;4.11,3.98,;5.64,4.14,;6.26,5.55,;5.36,6.8,;3.83,6.64,;3.2,5.23,;1.74,4.75,;.4,5.52,;-.93,4.75,;-.93,3.21,;-2.26,2.44,;-2.26,.9,;-.93,.13,;-.93,-1.41,;-2.26,-2.18,;-2.26,-3.72,;-3.6,-4.49,;-3.6,-6.03,;-2.26,-6.8,;-.93,-6.03,;-4.93,-3.72,;-4.93,-2.18,;-6.26,-1.41,;-3.6,-1.41,;-3.6,.13,;.4,2.44,;1.74,3.21,)| Show InChI InChI=1S/C26H31N7O2/c1-16-2-5-18(6-3-16)33-21-13-27-9-8-19(21)20-12-28-26(31-25(20)33)30-23-7-4-17-14-32(10-11-34)15-22(35)24(17)29-23/h4,7-9,12-13,16,18,22,34-35H,2-3,5-6,10-11,14-15H2,1H3,(H,28,29,30,31)/t16-,18-,22? | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 19.2 | n/a | n/a | n/a | n/a | 7.4 | n/a |
Amgen Inc.
US Patent
| Assay Description
The CDK4 and CDK1 inhibitory activity of the CDK4/6-FLT3 inhibitors was determined with a filtration kinase assay. The compounds, kinase and substrat... |
US Patent US8623885 (2014)
BindingDB Entry DOI: 10.7270/Q2DZ06Z1 |
More data for this
Ligand-Target Pair | |
Cyclin-dependent kinase 4
(Homo sapiens (Human)) | BDBM112474
(US8623885, 15)Show SMILES C[C@H]1CC[C@@H](CC1)n1c2cnccc2c2cnc(Nc3ccc4CN(CCO)CC(C)c4n3)nc12 |r,w:29.31,wU:4.7,wD:1.0,(4.8,-3.21,;4.4,-1.73,;5.49,-.64,;5.09,.85,;3.6,1.25,;2.51,.16,;2.91,-1.33,;3.2,2.74,;4.11,3.98,;5.64,4.14,;6.26,5.55,;5.36,6.8,;3.83,6.64,;3.2,5.23,;1.74,4.75,;.4,5.52,;-.93,4.75,;-.93,3.21,;-2.26,2.44,;-2.26,.9,;-.93,.13,;-.93,-1.41,;-2.26,-2.18,;-2.26,-3.72,;-3.6,-4.49,;-3.6,-6.03,;-2.26,-6.8,;-.93,-6.03,;-4.93,-3.72,;-4.93,-2.18,;-6.26,-1.41,;-3.6,-1.41,;-3.6,.13,;.4,2.44,;1.74,3.21,)| Show InChI InChI=1S/C27H33N7O/c1-17-3-6-20(7-4-17)34-23-14-28-10-9-21(23)22-13-29-27(32-26(22)34)31-24-8-5-19-16-33(11-12-35)15-18(2)25(19)30-24/h5,8-10,13-14,17-18,20,35H,3-4,6-7,11-12,15-16H2,1-2H3,(H,29,30,31,32)/t17-,18?,20- | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 20.3 | n/a | n/a | n/a | n/a | 7.4 | n/a |
Amgen Inc.
US Patent
| Assay Description
The CDK4 and CDK1 inhibitory activity of the CDK4/6-FLT3 inhibitors was determined with a filtration kinase assay. The compounds, kinase and substrat... |
US Patent US8623885 (2014)
BindingDB Entry DOI: 10.7270/Q2DZ06Z1 |
More data for this
Ligand-Target Pair | |
Receptor-type tyrosine-protein kinase FLT3
(Homo sapiens (Human)) | BDBM112466
(US8623885, 7)Show SMILES C[C@H]1CC[C@@H](CC1)n1c2cnccc2c2cnc(Nc3ccc4CN(CCC(F)(F)F)CCc4n3)nc12 |r,wU:4.7,wD:1.0,(4.13,-2.93,;3.73,-1.44,;4.82,-.35,;4.42,1.13,;2.93,1.53,;1.84,.44,;2.24,-1.04,;2.53,3.02,;3.44,4.26,;4.97,4.43,;5.6,5.83,;4.69,7.08,;3.16,6.92,;2.53,5.51,;1.07,5.03,;-.26,5.8,;-1.6,5.03,;-1.6,3.49,;-2.93,2.72,;-2.93,1.18,;-1.6,.41,;-1.6,-1.13,;-2.93,-1.9,;-2.93,-3.44,;-4.26,-4.21,;-4.26,-5.75,;-2.93,-6.52,;-2.93,-8.06,;-2.93,-9.6,;-4.47,-8.06,;-1.39,-8.06,;-5.6,-3.44,;-5.6,-1.9,;-4.26,-1.13,;-4.26,.41,;-.26,2.72,;1.07,3.49,)| Show InChI InChI=1S/C27H30F3N7/c1-17-2-5-19(6-3-17)37-23-15-31-11-8-20(23)21-14-32-26(35-25(21)37)34-24-7-4-18-16-36(12-9-22(18)33-24)13-10-27(28,29)30/h4,7-8,11,14-15,17,19H,2-3,5-6,9-10,12-13,16H2,1H3,(H,32,33,34,35)/t17-,19- | PDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 21.4 | n/a | n/a | n/a | n/a | 7.6 | n/a |
Amgen Inc.
US Patent
| Assay Description
The FLT3 inhibitory activity of the CDK4/6-FLT3 inhibitors was determined with a HTRF kinase assay. The FLT3 enzyme (GST-FLT3 fusion) was purchased f... |
US Patent US8623885 (2014)
BindingDB Entry DOI: 10.7270/Q2DZ06Z1 |
More data for this
Ligand-Target Pair | |
Cyclin-dependent kinase 4
(Homo sapiens (Human)) | BDBM112472
(US8623885, 13)Show SMILES C[C@H]1CC[C@@H](CC1)n1c2cnccc2c2cnc(Nc3ccc4CNCC(C)c4n3)nc12 |r,w:26.28,wU:4.7,wD:1.0,(4.8,-4.37,;4.4,-2.88,;5.49,-1.79,;5.09,-.3,;3.6,.09,;2.51,-.99,;2.91,-2.48,;3.2,1.58,;4.11,2.83,;5.64,2.99,;6.26,4.4,;5.36,5.64,;3.83,5.48,;3.2,4.07,;1.74,3.6,;.4,4.37,;-.93,3.6,;-.93,2.06,;-2.26,1.29,;-2.26,-.25,;-.93,-1.02,;-.93,-2.56,;-2.26,-3.33,;-2.26,-4.87,;-3.6,-5.64,;-4.93,-4.87,;-4.93,-3.33,;-6.26,-2.56,;-3.6,-2.56,;-3.6,-1.02,;.4,1.29,;1.74,2.06,)| Show InChI InChI=1S/C25H29N7/c1-15-3-6-18(7-4-15)32-21-14-26-10-9-19(21)20-13-28-25(31-24(20)32)30-22-8-5-17-12-27-11-16(2)23(17)29-22/h5,8-10,13-16,18,27H,3-4,6-7,11-12H2,1-2H3,(H,28,29,30,31)/t15-,16?,18- | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 31.3 | n/a | n/a | n/a | n/a | 7.4 | n/a |
Amgen Inc.
US Patent
| Assay Description
The CDK4 and CDK1 inhibitory activity of the CDK4/6-FLT3 inhibitors was determined with a filtration kinase assay. The compounds, kinase and substrat... |
US Patent US8623885 (2014)
BindingDB Entry DOI: 10.7270/Q2DZ06Z1 |
More data for this
Ligand-Target Pair | |
Receptor-type tyrosine-protein kinase FLT3
(Homo sapiens (Human)) | BDBM112478
(US8623885, 19)Show SMILES COc1cc2c(cn1)n([C@H]1CC[C@H](C)CC1)c1nc(Nc3ccc4CNCCc4n3)ncc21 |r,wU:9.9,wD:12.13,(4.41,6.97,;5.32,5.72,;4.69,4.32,;3.16,4.15,;2.53,2.75,;3.44,1.5,;4.97,1.66,;5.6,3.07,;2.53,.26,;2.93,-1.23,;4.42,-1.63,;4.82,-3.12,;3.73,-4.21,;4.13,-5.69,;2.24,-3.81,;1.84,-2.32,;1.07,.73,;-.26,-.04,;-1.6,.73,;-2.93,-.04,;-2.93,-1.58,;-1.6,-2.35,;-1.6,-3.89,;-2.93,-4.66,;-2.93,-6.2,;-4.26,-6.97,;-5.6,-6.2,;-5.6,-4.66,;-4.26,-3.89,;-4.26,-2.35,;-1.6,2.27,;-.26,3.04,;1.07,2.27,)| Show InChI InChI=1S/C25H29N7O/c1-15-3-6-17(7-4-15)32-21-14-27-23(33-2)11-18(21)19-13-28-25(31-24(19)32)30-22-8-5-16-12-26-10-9-20(16)29-22/h5,8,11,13-15,17,26H,3-4,6-7,9-10,12H2,1-2H3,(H,28,29,30,31)/t15-,17- | PDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 33 | n/a | n/a | n/a | n/a | 7.6 | n/a |
Amgen Inc.
US Patent
| Assay Description
The FLT3 inhibitory activity of the CDK4/6-FLT3 inhibitors was determined with a HTRF kinase assay. The FLT3 enzyme (GST-FLT3 fusion) was purchased f... |
US Patent US8623885 (2014)
BindingDB Entry DOI: 10.7270/Q2DZ06Z1 |
More data for this
Ligand-Target Pair | |
Cyclin-dependent kinase 4
(Homo sapiens (Human)) | BDBM112481
(US8623885, 22)Show SMILES OCC(=O)N1CCc2nc(Nc3ncc4c5ccncc5n(C5CCCC5)c4n3)ccc2C1 Show InChI InChI=1S/C24H25N7O2/c32-14-22(33)30-10-8-19-15(13-30)5-6-21(27-19)28-24-26-11-18-17-7-9-25-12-20(17)31(23(18)29-24)16-3-1-2-4-16/h5-7,9,11-12,16,32H,1-4,8,10,13-14H2,(H,26,27,28,29) | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 36 | n/a | n/a | n/a | n/a | 7.4 | n/a |
Amgen Inc.
US Patent
| Assay Description
The CDK4 and CDK1 inhibitory activity of the CDK4/6-FLT3 inhibitors was determined with a filtration kinase assay. The compounds, kinase and substrat... |
US Patent US8623885 (2014)
BindingDB Entry DOI: 10.7270/Q2DZ06Z1 |
More data for this
Ligand-Target Pair | |
Receptor-type tyrosine-protein kinase FLT3
(Homo sapiens (Human)) | BDBM112467
(US8623885, 8)Show SMILES C[C@H]1CC[C@@H](CC1)n1c2cnccc2c2cnc(Nc3ccc4CN(CCS(C)(=O)=O)CCc4n3)nc12 |r,wU:4.7,wD:1.0,(4.13,-3.21,;3.73,-1.73,;4.82,-.64,;4.42,.85,;2.93,1.25,;1.84,.16,;2.24,-1.33,;2.53,2.74,;3.44,3.98,;4.97,4.14,;5.6,5.55,;4.69,6.8,;3.16,6.64,;2.53,5.23,;1.07,4.75,;-.26,5.52,;-1.6,4.75,;-1.6,3.21,;-2.93,2.44,;-2.93,.9,;-1.6,.13,;-1.6,-1.41,;-2.93,-2.18,;-2.93,-3.72,;-4.26,-4.49,;-4.26,-6.03,;-2.93,-6.8,;-1.6,-6.03,;-.26,-6.8,;-2.37,-4.69,;-.83,-4.69,;-5.6,-3.72,;-5.6,-2.18,;-4.26,-1.41,;-4.26,.13,;-.26,2.44,;1.07,3.21,)| Show InChI InChI=1S/C27H33N7O2S/c1-18-3-6-20(7-4-18)34-24-16-28-11-9-21(24)22-15-29-27(32-26(22)34)31-25-8-5-19-17-33(12-10-23(19)30-25)13-14-37(2,35)36/h5,8-9,11,15-16,18,20H,3-4,6-7,10,12-14,17H2,1-2H3,(H,29,30,31,32)/t18-,20- | PDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 36.1 | n/a | n/a | n/a | n/a | 7.6 | n/a |
Amgen Inc.
US Patent
| Assay Description
The FLT3 inhibitory activity of the CDK4/6-FLT3 inhibitors was determined with a HTRF kinase assay. The FLT3 enzyme (GST-FLT3 fusion) was purchased f... |
US Patent US8623885 (2014)
BindingDB Entry DOI: 10.7270/Q2DZ06Z1 |
More data for this
Ligand-Target Pair | |
Cyclin-dependent kinase 4
(Homo sapiens (Human)) | BDBM112466
(US8623885, 7)Show SMILES C[C@H]1CC[C@@H](CC1)n1c2cnccc2c2cnc(Nc3ccc4CN(CCC(F)(F)F)CCc4n3)nc12 |r,wU:4.7,wD:1.0,(4.13,-2.93,;3.73,-1.44,;4.82,-.35,;4.42,1.13,;2.93,1.53,;1.84,.44,;2.24,-1.04,;2.53,3.02,;3.44,4.26,;4.97,4.43,;5.6,5.83,;4.69,7.08,;3.16,6.92,;2.53,5.51,;1.07,5.03,;-.26,5.8,;-1.6,5.03,;-1.6,3.49,;-2.93,2.72,;-2.93,1.18,;-1.6,.41,;-1.6,-1.13,;-2.93,-1.9,;-2.93,-3.44,;-4.26,-4.21,;-4.26,-5.75,;-2.93,-6.52,;-2.93,-8.06,;-2.93,-9.6,;-4.47,-8.06,;-1.39,-8.06,;-5.6,-3.44,;-5.6,-1.9,;-4.26,-1.13,;-4.26,.41,;-.26,2.72,;1.07,3.49,)| Show InChI InChI=1S/C27H30F3N7/c1-17-2-5-19(6-3-17)37-23-15-31-11-8-20(23)21-14-32-26(35-25(21)37)34-24-7-4-18-16-36(12-9-22(18)33-24)13-10-27(28,29)30/h4,7-8,11,14-15,17,19H,2-3,5-6,9-10,12-13,16H2,1H3,(H,32,33,34,35)/t17-,19- | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 52.4 | n/a | n/a | n/a | n/a | 7.4 | n/a |
Amgen Inc.
US Patent
| Assay Description
The CDK4 and CDK1 inhibitory activity of the CDK4/6-FLT3 inhibitors was determined with a filtration kinase assay. The compounds, kinase and substrat... |
US Patent US8623885 (2014)
BindingDB Entry DOI: 10.7270/Q2DZ06Z1 |
More data for this
Ligand-Target Pair | |
Cyclin-dependent kinase 4
(Homo sapiens (Human)) | BDBM112468
(US8623885, 9)Show SMILES C[C@H]1CC[C@@H](CC1)n1c2cnccc2c2cnc(Nc3ccc4CN(CCF)CCc4n3)nc12 |r,wU:4.7,wD:1.0,(4.13,-3.21,;3.73,-1.73,;4.82,-.64,;4.42,.85,;2.93,1.25,;1.84,.16,;2.24,-1.33,;2.53,2.74,;3.44,3.98,;4.97,4.14,;5.6,5.55,;4.69,6.8,;3.16,6.64,;2.53,5.23,;1.07,4.75,;-.26,5.52,;-1.6,4.75,;-1.6,3.21,;-2.93,2.44,;-2.93,.9,;-1.6,.13,;-1.6,-1.41,;-2.93,-2.18,;-2.93,-3.72,;-4.26,-4.49,;-4.26,-6.03,;-2.93,-6.8,;-1.6,-6.03,;-5.6,-3.72,;-5.6,-2.18,;-4.26,-1.41,;-4.26,.13,;-.26,2.44,;1.07,3.21,)| Show InChI InChI=1S/C26H30FN7/c1-17-2-5-19(6-3-17)34-23-15-28-11-8-20(23)21-14-29-26(32-25(21)34)31-24-7-4-18-16-33(13-10-27)12-9-22(18)30-24/h4,7-8,11,14-15,17,19H,2-3,5-6,9-10,12-13,16H2,1H3,(H,29,30,31,32)/t17-,19- | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 72.8 | n/a | n/a | n/a | n/a | 7.4 | n/a |
Amgen Inc.
US Patent
| Assay Description
The CDK4 and CDK1 inhibitory activity of the CDK4/6-FLT3 inhibitors was determined with a filtration kinase assay. The compounds, kinase and substrat... |
US Patent US8623885 (2014)
BindingDB Entry DOI: 10.7270/Q2DZ06Z1 |
More data for this
Ligand-Target Pair | |
Receptor-type tyrosine-protein kinase FLT3
(Homo sapiens (Human)) | BDBM112470
(US8623885, 11)Show SMILES C[C@H]1CC[C@@H](CC1)n1c2cnccc2c2cnc(Nc3cc4CNCCc4cn3)nc12 |r,wU:4.7,wD:1.0,(3.46,-4.37,;3.06,-2.88,;4.15,-1.79,;3.75,-.3,;2.27,.09,;1.18,-.99,;1.58,-2.48,;1.87,1.58,;2.77,2.83,;4.3,2.99,;4.93,4.4,;4.03,5.64,;2.49,5.48,;1.87,4.07,;.4,3.6,;-.93,4.37,;-2.26,3.6,;-2.26,2.06,;-3.6,1.29,;-3.6,-.25,;-2.26,-1.02,;-2.26,-2.56,;-.93,-3.33,;-.93,-4.87,;-2.26,-5.64,;-3.6,-4.87,;-3.6,-3.33,;-4.93,-2.56,;-4.93,-1.02,;-.93,1.29,;.4,2.06,)| Show InChI InChI=1S/C24H27N7/c1-15-2-4-18(5-3-15)31-21-14-26-9-7-19(21)20-13-28-24(30-23(20)31)29-22-10-17-11-25-8-6-16(17)12-27-22/h7,9-10,12-15,18,25H,2-6,8,11H2,1H3,(H,27,28,29,30)/t15-,18- | PDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 73.7 | n/a | n/a | n/a | n/a | 7.6 | n/a |
Amgen Inc.
US Patent
| Assay Description
The FLT3 inhibitory activity of the CDK4/6-FLT3 inhibitors was determined with a HTRF kinase assay. The FLT3 enzyme (GST-FLT3 fusion) was purchased f... |
US Patent US8623885 (2014)
BindingDB Entry DOI: 10.7270/Q2DZ06Z1 |
More data for this
Ligand-Target Pair | |
Cyclin-dependent kinase 4
(Homo sapiens (Human)) | BDBM112465
(US8623885, 6)Show SMILES C[C@H]1CC[C@@H](CC1)n1c2cnccc2c2cnc(Nc3ccc4CN(CCc4n3)C(=O)C(O)=O)nc12 |r,wU:4.7,wD:1.0,(4.13,-2.44,;3.73,-.96,;4.82,.13,;4.42,1.62,;2.93,2.02,;1.84,.93,;2.24,-.56,;2.53,3.51,;3.44,4.75,;4.97,4.91,;5.6,6.32,;4.69,7.57,;3.16,7.41,;2.53,6,;1.07,5.52,;-.26,6.29,;-1.6,5.52,;-1.6,3.98,;-2.93,3.21,;-2.93,1.67,;-1.6,.9,;-1.6,-.64,;-2.93,-1.41,;-2.93,-2.95,;-4.26,-3.72,;-5.6,-2.95,;-5.6,-1.41,;-4.26,-.64,;-4.26,.9,;-4.26,-5.26,;-5.6,-6.03,;-2.93,-6.03,;-1.6,-5.26,;-2.93,-7.57,;-.26,3.21,;1.07,3.98,)| Show InChI InChI=1S/C26H27N7O3/c1-15-2-5-17(6-3-15)33-21-13-27-10-8-18(21)19-12-28-26(31-23(19)33)30-22-7-4-16-14-32(24(34)25(35)36)11-9-20(16)29-22/h4,7-8,10,12-13,15,17H,2-3,5-6,9,11,14H2,1H3,(H,35,36)(H,28,29,30,31)/t15-,17- | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 120 | n/a | n/a | n/a | n/a | 7.4 | n/a |
Amgen Inc.
US Patent
| Assay Description
The CDK4 and CDK1 inhibitory activity of the CDK4/6-FLT3 inhibitors was determined with a filtration kinase assay. The compounds, kinase and substrat... |
US Patent US8623885 (2014)
BindingDB Entry DOI: 10.7270/Q2DZ06Z1 |
More data for this
Ligand-Target Pair | |
Receptor-type tyrosine-protein kinase FLT3
(Homo sapiens (Human)) | BDBM112479
(US8623885, 20)Show SMILES COc1cc2c(cn1)n([C@H]1CC[C@H](C)CC1)c1nc(Nc3ccc4CN(CCc4n3)C(=O)CO)ncc21 |r,wU:9.9,wD:12.13,(4.41,8.12,;5.32,6.88,;4.69,5.47,;3.16,5.31,;2.53,3.9,;3.44,2.66,;4.97,2.82,;5.6,4.22,;2.53,1.41,;2.93,-.08,;4.42,-.48,;4.82,-1.96,;3.73,-3.05,;4.13,-4.54,;2.24,-2.65,;1.84,-1.17,;1.07,1.89,;-.26,1.12,;-1.6,1.89,;-2.93,1.12,;-2.93,-.42,;-1.6,-1.19,;-1.6,-2.73,;-2.93,-3.5,;-2.93,-5.04,;-4.26,-5.81,;-5.6,-5.04,;-5.6,-3.5,;-4.26,-2.73,;-4.26,-1.19,;-4.26,-7.35,;-5.6,-8.12,;-2.93,-8.12,;-1.6,-7.35,;-1.6,3.43,;-.26,4.2,;1.07,3.43,)| Show InChI InChI=1S/C27H31N7O3/c1-16-3-6-18(7-4-16)34-22-13-28-24(37-2)11-19(22)20-12-29-27(32-26(20)34)31-23-8-5-17-14-33(25(36)15-35)10-9-21(17)30-23/h5,8,11-13,16,18,35H,3-4,6-7,9-10,14-15H2,1-2H3,(H,29,30,31,32)/t16-,18- | PDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 144 | n/a | n/a | n/a | n/a | 7.6 | n/a |
Amgen Inc.
US Patent
| Assay Description
The FLT3 inhibitory activity of the CDK4/6-FLT3 inhibitors was determined with a HTRF kinase assay. The FLT3 enzyme (GST-FLT3 fusion) was purchased f... |
US Patent US8623885 (2014)
BindingDB Entry DOI: 10.7270/Q2DZ06Z1 |
More data for this
Ligand-Target Pair | |
Cyclin-dependent kinase 4
(Homo sapiens (Human)) | BDBM112470
(US8623885, 11)Show SMILES C[C@H]1CC[C@@H](CC1)n1c2cnccc2c2cnc(Nc3cc4CNCCc4cn3)nc12 |r,wU:4.7,wD:1.0,(3.46,-4.37,;3.06,-2.88,;4.15,-1.79,;3.75,-.3,;2.27,.09,;1.18,-.99,;1.58,-2.48,;1.87,1.58,;2.77,2.83,;4.3,2.99,;4.93,4.4,;4.03,5.64,;2.49,5.48,;1.87,4.07,;.4,3.6,;-.93,4.37,;-2.26,3.6,;-2.26,2.06,;-3.6,1.29,;-3.6,-.25,;-2.26,-1.02,;-2.26,-2.56,;-.93,-3.33,;-.93,-4.87,;-2.26,-5.64,;-3.6,-4.87,;-3.6,-3.33,;-4.93,-2.56,;-4.93,-1.02,;-.93,1.29,;.4,2.06,)| Show InChI InChI=1S/C24H27N7/c1-15-2-4-18(5-3-15)31-21-14-26-9-7-19(21)20-13-28-24(30-23(20)31)29-22-10-17-11-25-8-6-16(17)12-27-22/h7,9-10,12-15,18,25H,2-6,8,11H2,1H3,(H,27,28,29,30)/t15-,18- | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 257 | n/a | n/a | n/a | n/a | 7.4 | n/a |
Amgen Inc.
US Patent
| Assay Description
The CDK4 and CDK1 inhibitory activity of the CDK4/6-FLT3 inhibitors was determined with a filtration kinase assay. The compounds, kinase and substrat... |
US Patent US8623885 (2014)
BindingDB Entry DOI: 10.7270/Q2DZ06Z1 |
More data for this
Ligand-Target Pair | |
Cyclin-dependent kinase 4
(Homo sapiens (Human)) | BDBM112497
(US8623885, 18b)Show SMILES C[C@H]1CC[C@@H](CC1)n1c2cnccc2c2cnc(Nc3ccc4CN(C[C@H](C)c4n3)C(C)=O)nc12 |r,wU:4.7,wD:1.0,26.28,(4.8,-11.87,;4.4,-10.38,;5.49,-9.29,;5.09,-7.81,;3.6,-7.41,;2.51,-8.5,;2.91,-9.98,;3.2,-5.92,;4.11,-4.67,;5.64,-4.51,;6.26,-3.11,;5.36,-1.86,;3.83,-2.02,;3.2,-3.43,;1.74,-3.9,;.4,-3.13,;-.93,-3.9,;-.93,-5.44,;-2.26,-6.21,;-2.26,-7.75,;-.93,-8.52,;-.93,-10.06,;-2.26,-10.83,;-2.26,-12.37,;-3.6,-13.14,;-4.93,-12.37,;-4.93,-10.83,;-6.26,-10.06,;-3.6,-10.06,;-3.6,-8.52,;-3.6,-14.68,;-2.26,-15.45,;-4.93,-15.45,;.4,-6.21,;1.74,-5.44,)| Show InChI InChI=1S/C27H31N7O/c1-16-4-7-20(8-5-16)34-23-13-28-11-10-21(23)22-12-29-27(32-26(22)34)31-24-9-6-19-15-33(18(3)35)14-17(2)25(19)30-24/h6,9-13,16-17,20H,4-5,7-8,14-15H2,1-3H3,(H,29,30,31,32)/t16-,17-,20-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 463 | n/a | n/a | n/a | n/a | 7.4 | n/a |
Amgen Inc.
US Patent
| Assay Description
The CDK4 and CDK1 inhibitory activity of the CDK4/6-FLT3 inhibitors was determined with a filtration kinase assay. The compounds, kinase and substrat... |
US Patent US8623885 (2014)
BindingDB Entry DOI: 10.7270/Q2DZ06Z1 |
More data for this
Ligand-Target Pair | |
Cyclin-dependent kinase 4
(Homo sapiens (Human)) | BDBM112479
(US8623885, 20)Show SMILES COc1cc2c(cn1)n([C@H]1CC[C@H](C)CC1)c1nc(Nc3ccc4CN(CCc4n3)C(=O)CO)ncc21 |r,wU:9.9,wD:12.13,(4.41,8.12,;5.32,6.88,;4.69,5.47,;3.16,5.31,;2.53,3.9,;3.44,2.66,;4.97,2.82,;5.6,4.22,;2.53,1.41,;2.93,-.08,;4.42,-.48,;4.82,-1.96,;3.73,-3.05,;4.13,-4.54,;2.24,-2.65,;1.84,-1.17,;1.07,1.89,;-.26,1.12,;-1.6,1.89,;-2.93,1.12,;-2.93,-.42,;-1.6,-1.19,;-1.6,-2.73,;-2.93,-3.5,;-2.93,-5.04,;-4.26,-5.81,;-5.6,-5.04,;-5.6,-3.5,;-4.26,-2.73,;-4.26,-1.19,;-4.26,-7.35,;-5.6,-8.12,;-2.93,-8.12,;-1.6,-7.35,;-1.6,3.43,;-.26,4.2,;1.07,3.43,)| Show InChI InChI=1S/C27H31N7O3/c1-16-3-6-18(7-4-16)34-22-13-28-24(37-2)11-19(22)20-12-29-27(32-26(20)34)31-23-8-5-17-14-33(25(36)15-35)10-9-21(17)30-23/h5,8,11-13,16,18,35H,3-4,6-7,9-10,14-15H2,1-2H3,(H,29,30,31,32)/t16-,18- | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 847 | n/a | n/a | n/a | n/a | 7.4 | n/a |
Amgen Inc.
US Patent
| Assay Description
The CDK4 and CDK1 inhibitory activity of the CDK4/6-FLT3 inhibitors was determined with a filtration kinase assay. The compounds, kinase and substrat... |
US Patent US8623885 (2014)
BindingDB Entry DOI: 10.7270/Q2DZ06Z1 |
More data for this
Ligand-Target Pair | |
Cyclin-dependent kinase 4
(Homo sapiens (Human)) | BDBM112478
(US8623885, 19)Show SMILES COc1cc2c(cn1)n([C@H]1CC[C@H](C)CC1)c1nc(Nc3ccc4CNCCc4n3)ncc21 |r,wU:9.9,wD:12.13,(4.41,6.97,;5.32,5.72,;4.69,4.32,;3.16,4.15,;2.53,2.75,;3.44,1.5,;4.97,1.66,;5.6,3.07,;2.53,.26,;2.93,-1.23,;4.42,-1.63,;4.82,-3.12,;3.73,-4.21,;4.13,-5.69,;2.24,-3.81,;1.84,-2.32,;1.07,.73,;-.26,-.04,;-1.6,.73,;-2.93,-.04,;-2.93,-1.58,;-1.6,-2.35,;-1.6,-3.89,;-2.93,-4.66,;-2.93,-6.2,;-4.26,-6.97,;-5.6,-6.2,;-5.6,-4.66,;-4.26,-3.89,;-4.26,-2.35,;-1.6,2.27,;-.26,3.04,;1.07,2.27,)| Show InChI InChI=1S/C25H29N7O/c1-15-3-6-17(7-4-15)32-21-14-27-23(33-2)11-18(21)19-13-28-25(31-24(19)32)30-22-8-5-16-12-26-10-9-20(16)29-22/h5,8,11,13-15,17,26H,3-4,6-7,9-10,12H2,1-2H3,(H,28,29,30,31)/t15-,17- | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 1.79E+3 | n/a | n/a | n/a | n/a | 7.4 | n/a |
Amgen Inc.
US Patent
| Assay Description
The CDK4 and CDK1 inhibitory activity of the CDK4/6-FLT3 inhibitors was determined with a filtration kinase assay. The compounds, kinase and substrat... |
US Patent US8623885 (2014)
BindingDB Entry DOI: 10.7270/Q2DZ06Z1 |
More data for this
Ligand-Target Pair | |
Search and Browse
